

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Vabysmo 120 mg/mL solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Faricimab is a humanised antibody produced in mammalian Chinese Hamster Ovary (CHO) cell culture by recombinant DNA technology.

One mL of solution contains 120 mg of faricimab.

Each vial contains 28.8 mg faricimab in 0.24 mL solution. This provides a usable amount to deliver a single dose of 0.05 mL solution containing 6 mg of faricimab.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection

Clear to opalescent, colourless to brownish-yellow solution, with a pH of 5.5 and an osmolality of 270-370 mOsm/kg.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Vabysmo is indicated for the treatment of adult patients with:

- neovascular (wet) age-related macular degeneration (nAMD),
- visual impairment due to diabetic macular oedema (DME).

4.2 Posology and method of administration

This medicinal product must be administered by a qualified physician experienced in intravitreal injections. Each vial should only be used for the treatment of a single eye.

Posology

Neovascular (wet) age-related macular degeneration (nAMD)

The recommended dose is 6 mg (0.05 mL solution) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses.

Thereafter, an assessment of disease activity based on anatomic and/or visual outcomes is recommended 20 and/or 24 weeks after treatment initiation so that treatment can be individualised. In patients without disease activity, administration of faricimab every 16 weeks (4 months) should be considered. In patients with disease activity, treatment every 8 weeks (2 months) or 12 weeks (3 months) should be considered. There is limited safety data on treatment intervals of 8 weeks or less between injections. Monitoring between the dosing visits should be scheduled based on the patient's

status and at the physician's discretion, but there is no requirement for monthly monitoring between injections.

Visual impairment due to diabetic macular oedema (DME)

The recommended dose is 6 mg (0.05 mL solution) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses.

Thereafter, treatment is individualised using a treat-and-extend approach. Based on the physician's judgement of the patient's anatomic and/or visual outcomes, the dosing interval may be extended up to every 16 weeks (4 months), in increments of up to 4 weeks. If anatomic and/or visual outcomes change, the treatment interval should be adjusted accordingly, and interval reduction should be implemented if anatomic and/or visual outcomes deteriorate (see section 5.1). Treatment intervals shorter than 4 weeks between injections have not been studied. Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion, but there is no requirement for monthly monitoring between injections.

Duration of treatment

This medicinal product is intended for long-term treatment. If visual and/or anatomic outcomes indicate that the patient is not benefitting from continued treatment, treatment should be discontinued.

Delayed or missed dose

If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician's discretion.

Special populations

Elderly

No dose adjustment is required in patients aged 65 years or above (see section 5.2). Safety data in nAMD patients over 85 years is limited (see section 4.4).

Renal impairment

No dose adjustment is required in patients with renal impairment (see section 5.2).

Hepatic impairment

No dose adjustment is required in patients with hepatic impairment (see section 5.2).

Paediatric population

There is no relevant use of this medicinal product in the paediatric population for the indications of nAMD and DME.

Method of administration

For intravitreal use only.

Vabysmo should be inspected visually for particulate matter and discoloration prior to administration, and if present, the vial should not be used.

The intravitreal injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, a sterile drape and a sterile eyelid speculum (or equivalent). The patient's medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.8). Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid and ocular surface should be administered prior to the injection.

The injection needle should be inserted 3.5 to 4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of 0.05 mL is then delivered slowly; a different scleral site should be used for subsequent injections.

After injection, any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available.

Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. vision loss, eye pain, redness of the eye, photophobia, blurring of vision) without delay.

For instructions on handling of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active or suspected ocular or periocular infections.

Active intraocular inflammation.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.

Intravitreal injection-related reactions

Intravitreal injections, including those with faricimab, have been associated with endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment and retinal tear (see section 4.8). Proper aseptic injection techniques must always be used when administering Vabysmo. Patients should be instructed to report any symptoms, such as pain, loss of vision, photophobia, blurred vision, floaters, or redness, suggestive of endophthalmitis or any of the above-mentioned adverse reactions without delay, to permit prompt and appropriate management. Patients with increased frequency of injections may be at increased risk of procedural complications.

Intraocular pressure increases

Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including those with faricimab (see section 4.8). Special precaution is needed in patients with poorly controlled glaucoma (do not inject Vabysmo while the IOP is ≥ 30 mmHg). In all cases, both the IOP and perfusion of the optic nerve head must be monitored and managed appropriately.

Systemic effects

Systemic adverse events including arterial thromboembolic events have been reported following intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors and there is a theoretical risk that these may be related to VEGF inhibition. A low incidence rate of arterial thromboembolic events was observed in the faricimab clinical trials in patients with nAMD and DME. There are limited data on the safety of faricimab treatment in DME patients with high blood pressure ($\geq 140/90$ mmHg) and vascular disease, and in nAMD patients ≥ 85 years of age.

Immunogenicity

As this is a therapeutic protein, there is a potential for immunogenicity with faricimab (see section 4.8). Patients should be instructed to inform their physician of any signs or symptoms of intraocular inflammation such as vision loss, eye pain, increased sensitivity to light, floaters or worsening eye redness, which might be a clinical sign attributable to hypersensitivity against faricimab (see section 4.8).

Bilateral treatment

The safety and efficacy of faricimab administered in both eyes concurrently have not been studied. Bilateral treatment could cause bilateral ocular adverse reactions and/or potentially lead to an increase in systemic exposure, which could increase the risk of systemic adverse reactions. Until data for bilateral use become available, this is a theoretical risk for faricimab.

Concomitant use of other anti-VEGF

There are no data available on the concomitant use of faricimab with anti-VEGF medicinal products in the same eye. Faricimab should not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).

Withholding treatment

Treatment should be withheld in patients with:

- Rhegmatogenous retinal detachment, stage 3 or 4 macular holes, retinal break; treatment should not be resumed until an adequate repair has been performed.
- Treatment related decrease in Best Corrected Visual Acuity (BCVA) of ≥ 30 letters compared with the last assessment of visual acuity; treatment should not be resumed earlier than the next scheduled treatment.
- An intraocular pressure of ≥ 30 mmHg.
- A subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is $\geq 50\%$, of the total lesion area.
- Performed or planned intraocular surgery within the previous or next 28 days; treatment should not be resumed earlier than the next scheduled treatment.

Retinal pigment epithelial tear

Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for nAMD, include a large and/or high pigment epithelial detachment. When initiating faricimab therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears. Retinal pigment epithelial (RPE) tear is a complication of pigment epithelial detachment (PED) in patients with nAMD. RPE tears are common in nAMD patients with PED, treated with IVT anti-VEGF agents including faricimab. There was a higher rate of RPE tear in the faricimab group (2.9%) compared to aflibercept group (1.4%). The majority of events occurred during the loading phase, and were mild to moderate, without impact on vision.

Populations with limited data

There is only limited experience in the treatment of nAMD patients ≥ 85 years, and DME patients with type I diabetes, patients with HbA1c over 10%, patients with high-risk proliferative diabetic retinopathy (DR), high blood pressure ($\geq 140/90$ mmHg) and vascular disease, sustained dosing intervals shorter than Q8W, or nAMD and DME patients with active systemic infections. There is limited safety information on sustained dosing intervals of 8 weeks or less and these may be associated with a higher risk of ocular and systemic adverse reactions, including serious adverse reactions. There is also no experience of treatment with faricimab in diabetic patients with uncontrolled hypertension. This lack of information should be considered by the physician when treating such patients.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Based on the biotransformation and elimination of faricimab (see section 5.2), no interactions are expected. However, faricimab should not be administered concurrently with other systemic or ocular anti-VEGF medicinal products (see section 4.4).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should use effective contraception during treatment and for at least 3 months following the last intravitreal injection of faricimab.

Pregnancy

There are no or limited amount of data from the use of faricimab in pregnant women. The systemic exposure to faricimab is low after ocular administration, but due to its mechanism of action (i.e. VEGF inhibition), faricimab must be regarded as potentially teratogenic and embryo-/foetotoxic (see section 5.3).

Faricimab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.

Breast-feeding

It is unknown whether faricimab is excreted in human milk. A risk to the breast-fed newborn/infant cannot be excluded. Vabysmo should not be used during breast-feeding. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from faricimab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

No effects on reproductive organs or fertility were observed in a 6-month cynomolgus monkey study with faricimab (see section 5.3).

4.7 Effects on ability to drive and use machines

Vabysmo has a minor influence on the ability to drive and use machines. Temporary visual disturbances may occur following the intravitreal injection and the associated eye examination. Patients should not drive or use machines until visual function has recovered sufficiently.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions were cataract (11%), conjunctival haemorrhage (7%), IOP increased (4%), vitreous floaters (4%), eye pain (3%) and retinal pigment epithelial tear (nAMD only) (3%).

The most serious adverse reactions were uveitis (0.5%), vitritis (0.3%), endophthalmitis (0.3%), retinal tear (0.2%), and rhegmatogenous retinal detachment (< 0.1%) (see section 4.4).

Tabulated list of adverse reactions

The adverse reactions reported in clinical studies are listed according to the MedDRA system organ class and ranked by frequency using the following convention: Very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1: Frequencies of adverse reactions

MedDRA System organ class	Frequency category
Eye disorders	
Cataract	Very common
Conjunctival haemorrhage	Common
Vitreous floaters	Common
Retinal pigment epithelial tear (nAMD only)	Common
Increased intraocular pressure	Common
Eye pain	Common
Increased lacrimation	Common
Eye irritation	Uncommon
Vitreous haemorrhage	Uncommon
Ocular discomfort	Uncommon
Eye pruritus	Uncommon
Corneal abrasion	Uncommon
Ocular hyperaemia	Uncommon
Blurred vision	Uncommon
Iritis	Uncommon
Uveitis	Uncommon
Iridocyclitis	Uncommon
Vitritis	Uncommon
Sensation of foreign body	Uncommon
Endophthalmitis	Uncommon
Retinal tear	Uncommon
Conjunctival hyperaemia	Uncommon
Reduced visual acuity	Uncommon
Transiently reduced visual acuity	Rare
Rhegmatogenous retinal detachment	Rare

Description of selected adverse reactions

Product-class-related adverse reactions

There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the faricimab clinical trials in patients with nAMD and DME (see section 4.4). Across indications, no notable difference between the groups treated with faricimab and the comparator were observed.

Immunogenicity

There is a potential for an immune response in patients treated with faricimab (see section 4.4). After dosing with faricimab for up to 48 (nAMD) and 100 (DME) weeks, treatment-emergent anti-faricimab antibodies were detected in approximately 10.4% and 9.6% of patients with nAMD and DME respectively. The clinical significance of anti-faricimab antibodies on safety is unclear at this time. The incidence of intraocular inflammation in anti-faricimab antibody positive patients was 5/75 (6.7%; nAMD) and 15/128 (11.7%; DME), and in anti-faricimab antibody negative patients was 7/582 (1.2%; nAMD) and 5/1124 (0.4%; DME). The incidence of serious ocular adverse reactions in anti-faricimab antibody positive patients was 3/75 (4.0%; nAMD) and 14/128 (10.9%; DME) and in anti-faricimab antibody negative patients was 8/582 (1.4%; nAMD) and 45/1124 (4.0%; DME). Anti-faricimab antibodies were not associated with an impact on clinical efficacy or systemic pharmacokinetics.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via [the national reporting system](#) listed in [Appendix V](#).

4.9 Overdose

Overdosing with greater than recommended injection volume may increase intraocular pressure. In the event of overdose, IOP should be monitored and, if deemed necessary by the treating physician, appropriate treatment should be initiated.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Ophthalmologicals, antineovascularisation agents, ATC code: S01LA09

Mechanism of action

Faricimab is a humanised bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralisation of both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A).

Ang-2 causes vascular instability by promoting endothelial destabilisation, pericyte loss, and pathological angiogenesis, thus potentiating vascular leakage and inflammation. It also sensitises blood vessels to the activity of VEGF-A resulting in further vascular destabilisation. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularisation.

By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.

Pharmacodynamic effects

A suppression from baseline of median ocular free Ang-2 and free VEGF-A concentrations was observed from day 7 onwards in the four Phase III studies described hereafter.

nAMD

In TENAYA and LUCERNE, objective, pre-specified visual and anatomic criteria, as well as treating physician clinical assessment, were used to guide treatment decisions at the disease activity assessment time points (week 20 and week 24).

Reductions in mean central subfield thickness (CST) were observed from baseline through to week 48 with faricimab, and were comparable to those observed with aflibercept. The mean CST reduction from baseline through the primary endpoint visits (averaged at weeks 40-48) was -137 μm and -137 μm for faricimab dosed up to every 16 weeks (Q16W) versus -129 μm and -131 μm with aflibercept, in TENAYA and LUCERNE, respectively.

At week 48, in both studies there was a comparable effect of faricimab and aflibercept on the reduction of IRF, SRF, and pigment epithelial detachment (PED). There were also comparable changes in total CNV lesion area and reductions in CNV leakage area from baseline for patients in the faricimab and aflibercept treatment arms.

DME

In YOSEMITE and RHINE, anatomic parameters related to macular oedema were part of the disease activity assessments guiding treatment decisions.

The mean CST reduction from baseline at the primary endpoint visits (averaged at weeks 48-56) was numerically greater than those observed with aflibercept, with -207 μm and -197 μm in patients treated with faricimab Q8W and faricimab up to Q16W adjustable dosing as compared to -170 μm in aflibercept Q8W patients in YOSEMITE; results were 196 μm , 188 μm and 170 μm , respectively in RHINE. Consistent reductions in CST were observed through Year 2. Greater proportions of patients in both faricimab arms achieved absence of IRF and absence of DME (defined as reaching CST below 325 μm) over time through year 2 as compared to aflibercept in both studies.

Clinical efficacy and safety

nAMD

The safety and efficacy of faricimab were assessed in two randomised, multi-centre, double-masked, active comparator-controlled, 2-year non-inferiority studies in patients with nAMD, TENAYA and LUCERNE. A total of 1,329 patients were enrolled in these and 1,326 patients received at least one dose (664 with faricimab). Patient ages ranged from 50 to 99 years with a mean [standard deviation; SD] of 75.9 [8.6] years.

In both studies, patients were randomised in a 1:1 ratio to one of two treatment arms:

- Faricimab 6 mg up to Q16W after four initial monthly doses
- Aflibercept 2 mg Q8W after three initial monthly doses

After the first four monthly doses (weeks 0, 4, 8, and 12) patients randomised to the faricimab arm received Q16W, every 12 weeks (Q12W) or Q8W dosing based on an assessment of disease activity at weeks 20 and 24, using objective pre-specified visual and anatomic criteria as well as treating physician clinical assessment. Patients remained on these fixed dosing intervals until week 60 without supplemental therapy.

Results

Both studies showed efficacy in the primary endpoint, defined as the mean change from baseline in BCVA when averaged over the week 40, 44, and 48 visits and measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score (Table 2). In both studies, faricimab up to Q16W treated patients had a non-inferior mean change from baseline in BCVA, as the patients treated with aflibercept Q8W. Improvements from baseline BCVA at week 48 are shown in Figure 1.

The proportion of patients on each of the different treatment intervals at week 48 in TENAYA and LUCERNE respectively was:

- Q16W, 46% and 45%
- Q12W, 34% and 33%
- Q8W, 20% and 22%

Table 2: Efficacy outcomes at the primary endpoint visits^a in TENAYA and LUCERNE

Efficacy Outcomes	TENAYA		LUCERNE	
	Faricimab up to Q16W N = 334	Aflibercept Q8W N = 337	Faricimab up to Q16W N = 331	Aflibercept Q8W N = 327
Mean change in BCVA as measured by ETDRS letter score from baseline (95% CI)	5.8 (4.6, 7.1)	5.1 (3.9, 6.4)	6.6 (5.3, 7.8)	6.6 (5.3, 7.8)
Difference in LS mean (95% CI)	0.7 (-1.1, 2.5)		0.0 (-1.7, 1.8)	
Proportion of patients with ≥ 15 letter gain from baseline (CMH weighted proportion, 95% CI)	20.0% (15.6%, 24.4%)	15.7% (11.9%, 19.6%)	20.2% (15.9%, 24.6%)	22.2% (17.7%, 26.8%)
Difference in CMH weighted % (95% CI)	4.3% (-1.6%, 10.1%)		-2.0% (-8.3%, 4.3%)	
Proportion of patients avoiding ≥ 15 letter loss from baseline (CMH weighted proportion, 95% CI)	95.4% (93.0%, 97.7%)	94.1% (91.5%, 96.7%)	95.8% (93.6%, 98.0%)	97.3% (95.5%, 99.1%)
Difference in CMH weighted % (95% CI)	1.3% (-2.2%, 4.8%)		-1.5% (-4.4%, 1.3%)	

^aAverage of weeks 40, 44 and 48

BCVA: Best Corrected Visual Acuity


ETDRS: Early Treatment Diabetic Retinopathy Study

CI: Confidence Interval

LS: Least Square

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Figure 1: Mean change in visual acuity from baseline to week 48; combined data from TENAYA and LUCERNE studies



In both TENAYA and LUCERNE, improvements from baseline in BCVA and CST at week 60 were comparable across the two treatment arms and consistent with those seen at week 48.

Efficacy results in all evaluable subgroups (e.g. age, gender, race, baseline visual acuity, lesion type, lesion size) in each study, and in the pooled analysis, were consistent with the results in the overall populations.

Across studies, faricimab up to Q16W showed improvement in pre-specified efficacy endpoint of mean change from baseline to week 48 in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score that was comparable to aflibercept Q8W, and exceeded the threshold of 4 points. The magnitude of these changes corresponds to a 15-letter gain in BCVA.

The incidence of ocular adverse events in the study eye was 38.3% and 37.2% and non-ocular adverse events was 52.1% and 54.8%, through Week 48 in the faricimab and aflibercept arms, respectively (see section 4.4 and 4.8).

DME

The safety and efficacy of faricimab were assessed in two randomised, multi-centre, double-masked, active comparator-controlled 2-year non-inferiority studies (YOSEMITE and RHINE) in patients with DME. A total of 1,891 patients were enrolled in the two studies with 1,622 (86%) patients completing the studies through week 100. A total of 1,887 patients were treated with at least one dose through week 56 (1,262 with faricimab). Patient ages ranged from 24 to 91 with a mean [SD] of 62.2 [9.9] years. The overall population included both anti-VEGF naive patients (78%) and patients who had been previously treated with a VEGF inhibitor prior to study participation (22%). In both studies, patients were randomised in a 1:1:1 ratio to one of the three treatment regimens:

- Faricimab 6 mg Q8W after the first 6 monthly doses.
- Faricimab 6 mg up to Q16W adjustable dosing administered in 4, 8, 12 or 16-week intervals after the first 4 monthly doses.
- Aflibercept 2 mg Q8W after the first 5 monthly doses.

In the Q16W adjustable dosing arm, the dosing followed a standardised treat-and-extend approach. The interval could be increased in 4-week increments or decreased in 4- or 8-week increments based on anatomic and/or visual outcomes, using data obtained only at study drug dosing visits.

Results

Both studies showed efficacy in the primary endpoint, defined as the mean change from baseline in BCVA at year 1 (average of the week 48, 52, and 56 visits), measured by the ETDRS Letter Score. In both studies, faricimab up to Q16W treated patients had a non-inferior mean change from baseline in BCVA, as the patients treated with aflibercept Q8W at year 1, and these vision gains were maintained through year 2. Detailed results of both studies are shown in Table 3, Table 4, and Figure 2 below.

After 4 initial monthly doses, the patients in the faricimab up to Q16W adjustable dosing arm could have received between the minimum of 6 and the maximum of 21 total injections through week 96. At week 52, 74% and 71% of patients in the faricimab up to Q16W adjustable dosing arm achieved a Q16W or Q12W dosing interval in YOSEMITE and RHINE, respectively (53% and 51% on Q16W, 21% and 20% on Q12W). Of these patients, 75% and 84% maintained \geq Q12W dosing without an interval reduction below Q12W through week 96; of the patients on Q16W at week 52, 70% and 82% of patients maintained Q16W dosing without an interval reduction through week 96 in YOSEMITE and RHINE, respectively. At week 96, 78% of patients in the faricimab up to Q16W adjustable dosing arm achieved a Q16W or Q12W dosing interval in both studies (60% and 64% on Q16W, 18% and 14% on Q12W). 4% and 6% of patients were extended to Q8W and stayed on \leq Q8W dosing intervals through week 96; 3% and 5% received only Q4W dosing in YOSEMITE and RHINE, respectively.

Detailed results from the analyses of YOSEMITE and RHINE studies are listed in Table 3, Table 4, and Figure 2 below.

Table 3: Efficacy outcomes at the year 1 primary endpoint visits^a and at year 2^b in YOSEMITE

Efficacy Outcomes	YOSEMITE					
	Year 1			Year 2		
	Faricimab Q8W N = 315	Faricimab up to Q16W adjustable dosing N = 313	Aflibercept Q8W N = 312	Faricimab Q8W N = 262	Faricimab up to Q16W adjustable dosing N = 270	Aflibercept Q8W N = 259
Mean change in BCVA as measured by ETDRS letter score from baseline (97.5% CI year 1 and 95% CI year 2)	10.7 (9.4, 12.0)	11.6 (10.3, 12.9)	10.9 (9.6, 12.2)	10.7 (9.4, 12.1)	10.7 (9.4, 12.1)	11.4 (10.0, 12.7)
Difference in LS mean (97.5% CI year 1, 95% CI year 2)	-0.2 (-2.0, 1.6)	0.7 (-1.1, 2.5)		-0.7 (-2.6, 1.2)	-0.7 (-2.5, 1.2)	
Proportion of patients who gained at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	29.2% (23.9%, 34.5%)	35.5% (30.1%, 40.9%)	31.8% (26.6%, 37.0%)	37.2% (31.4%, 42.9%)	38.2% (32.8%, 43.7%)	37.4% (31.7%, 43.0%)
Difference in CMH weighted % (95% CI year 1 and year 2)	-2.6% (-10.0%, 4.9%)	3.5% (-4.0%, 11.1%)		-0.2% (-8.2%, 7.8%)	0.2% (-7.6%, 8.1%)	
Proportion of patients who avoided loss of at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	98.1% (96.5%, 99.7%)	98.6% (97.2%, 100.0%)	98.9% (97.6%, 100.0%)	97.6% (95.7%, 99.5%)	97.8% (96.1%, 99.5%)	98.0% (96.2%, 99.7%)
Difference in CMH weighted % (95% CI year 1 and year 2)	-0.8% (-2.8%, 1.3%)	-0.3% (-2.2%, 1.5%)		-0.4% (-2.9%, 2.2%)	-0.2% (-2.6%, 2.2%)	

^aAverage of weeks 48, 52, 56. ^bAverage of weeks 92, 96, 100

BCVA: Best Corrected Visual Acuity

ETDRS: Early Treatment Diabetic Retinopathy Study

LS: Least Square

CI: Confidence Interval

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Note: CMH weighted % for aflibercept arm presented for faricimab Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for faricimab adjustable vs. aflibercept comparison is similar to the one shown above.

Table 4: Efficacy outcomes at the year 1 primary endpoint visits^a and at year 2^b in RHINE

Efficacy Outcomes	RHINE					
	Year 1			Year 2		
	Faricimab Q8W N = 317	Faricimab up to Q16W adjustable dosing N = 319	Aflibercept Q8W N = 315	Faricimab Q8W N = 259	Faricimab up to Q16W adjustable dosing N = 282	Aflibercept Q8W N = 254
Mean change in BCVA as measured by ETDRS letter score from baseline (97.5% CI year 1 and 95% CI year 2)	11.8 (10.6, 13.0)	10.8 (9.6, 11.9)	10.3 (9.1, 11.4)	10.9 (9.5, 12.3)	10.1 (8.7, 11.5)	9.4 (7.9, 10.8)
Difference in LS mean (97.5% CI year 1, 95% CI year 2)	1.5 (-0.1, 3.2)	0.5 (-1.1, 2.1)		1.5 (-0.5, 3.6)	0.7 (-1.3, 2.7)	
Proportion of patients who gained at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	33.8% (28.4%, 39.2%)	28.5% (23.6%, 33.3%)	30.3% (25.0%, 35.5%)	39.8% (34.0%, 45.6%)	31.1% (26.1%, 36.1%)	39.0% (33.2%, 44.8%)
Difference in CMH weighted % (95% CI year 1 and year 2)	3.5% (-4.0%, 11.1%)	-2.0% (-9.1%, 5.2%)		0.8% (-7.4%, 9.0%)	-8% (-15.7%, -0.3%)	
Proportion of patients who avoided loss of at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	98.9% (97.6%, 100.0%)	98.7% (97.4%, 100.0%)	98.6% (97.2%, 99.9%)	96.6% (94.4%, 98.8%)	96.8% (94.8%, 98.9%)	97.6% (95.7%, 99.5%)
Difference in CMH weighted % (95% CI year 1 and year 2)	0.3% (-1.6%, 2.1%)	0.0% (-1.8%, 1.9%)		-1.0% (-3.9%, 1.9%)	-0.7% (-3.5%, 2.0%)	

^aAverage of weeks 48, 52, 56; ^bAverage of weeks 92, 96, 100

BCVA: Best Corrected Visual Acuity

ETDRS: Early Treatment Diabetic Retinopathy Study


LS: Least Square

CI: Confidence Interval

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Note: CMH weighted % for aflibercept arm presented for faricimab Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for faricimab adjustable vs. aflibercept comparison is similar to the one shown above.

Figure 2: Mean change in visual acuity from baseline to year 2 (week 100); combined data from YOSEMITE and RHINE studies



Efficacy results in patients who were anti-VEGF treatment naive prior to study participation and in all the other evaluable subgroups (e.g. by age, gender, race, baseline HbA1c, baseline visual acuity) in each study were consistent with the results in the overall populations.

Across studies, faricimab Q8W and up to Q16W adjustable dosing showed improvements in the pre-specified efficacy endpoint of mean change from baseline to week 52 in the NEI VFQ-25 composite score that was comparable to aflibercept Q8W and exceeded the threshold of 4 points. Faricimab Q8W and up to Q16W adjustable dosing also demonstrated clinically meaningful improvements in the pre-specified efficacy endpoint of change from baseline to week 52 in the NEI VFQ-25 near activities, distance activities, and driving scores, that were comparable to aflibercept Q8W. The magnitude of these changes corresponds to a 15-letter gain in BCVA. Comparable proportions of patients treated with faricimab Q8W, faricimab up to Q16W adjustable dosing, and aflibercept Q8W experienced a clinically meaningful improvement of ≥ 4 -points from baseline to week 52 in the NEI VFQ-25 composite score, a pre-specified efficacy endpoint. These results were maintained at week 100.

An additional key efficacy outcome in DME studies was the change in the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS-DRSS) from baseline to week 52. Of the 1,891 patients enrolled in Studies YOSEMITE and RHINE, 708 and 720 patients were evaluable for DR endpoints.

The ETDRS-DRSS scores ranged from 10 to 71 at baseline.

The majority of patients, approximately 60%, had moderate to severe non-proliferative DR (DRSS 43/47/53) at baseline.

The proportion of patients who achieved ≥ 2 -step and ≥ 3 -step improvement from baseline in ETDRS-DRSS at week 52 and at week 96 are shown in Table 5 and Table 6 below.

Table 5: Proportion of patients who achieved ≥ 2 -step and ≥ 3 -step improvement from baseline in ETDRS-DRSS score at week 52 and at week 96 in YOSEMITE (DR evaluable population)

	YOSEMITE					
	52 Weeks			96 Weeks		
	Faricimab Q8W n = 237	Faricimab up to Q16W adjustable dosing n = 242	Aflibercept Q8W n = 229	Faricimab Q8W n = 220	Faricimab up to Q16W adjustable dosing n = 234	Aflibercept Q8W n = 221
Proportion of patients with ≥ 2 -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	46.0%	42.5%	35.8%	51.4%	42.8%	42.2%
Weighted Difference (97.5% CI year 1, 95% year 2)	10.2% (1.6%, 18.7%)	6.1% (-2.4%, 14.6%)		9.1% (0.0%, 18.2%)	0.0% (-8.9%, 8.9%)	
Proportion of patients with ≥ 3 -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	16.8%	15.5%	14.7%	22.4%	14.6%	20.9%
Weighted Difference (95% CI year 1 and year 2)	2.1% (-4.3%, 8.6%)	0.6% (-5.8%, 6.9%)		1.5% (-6.0%, 9.0%)	-6.7% (-13.6%, 0.1%)	

ETDRS-DRSS: Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale

CI: Confidence Interval

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Note: CMH weighted % for aflibercept arm presented for faricimab Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for faricimab adjustable vs. aflibercept comparison is similar to the one shown above.

Table 6: Proportion of patients who achieved ≥ 2 -step and ≥ 3 -step improvement from baseline in ETDRS-DRSS score at week 52 and at week 96 in RHINE (DR evaluable population)

	RHINE					
	52 Weeks			96 Weeks		
	Faricimab Q8W n = 231	Faricimab up to Q16W adjustable dosing n = 251	Aflibercept Q8W n = 238	Faricimab Q8W n = 214	Faricimab up to Q16W adjustable dosing n = 228	Aflibercept Q8W n = 203
Proportion of patients with ≥ 2 -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	44.2%	43.7%	46.8%	53.5%	44.3%	43.8%
Weighted Difference (97.5% CI year 1, 95% year 2)	-2.6% (-11.3%, 6.2%)	-3.5% (-12.1%, 5.1%)		9.7% (0.4%, 19.1%)	0.3% (-8.9%, 9.5%)	
Proportion of patients with ≥ 3 -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	16.7%	18.9%	19.4%	25.1%	19.3%	21.8%
Weighted Difference (95% CI year 1 and year 2)	-0.2% (-5.8%, 5.3%)	-1.1% (-8.0%, 5.9%)		3.3% (-4.6%, 11.3%)	-2.7% (-10.2%, 4.8%)	

ETDRS-DRSS: Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale

CI: Confidence Interval

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Note: CMH weighted % for aflibercept arm presented for Faricimab Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for Faricimab adjustable vs. aflibercept comparison is similar to the one shown above.

Treatment effects in evaluable subgroups (e.g. by previous anti-VEGF treatment, age, gender, race, baseline HbA1c, and baseline visual acuity) in each study were generally consistent with the results in the overall population.

Treatment effects in subgroups by DR severity at baseline were different and showed the greatest ≥ 2 -step DRSS improvements among patients with moderately severe and severe non-proliferative DR with approximately 90% of patients achieving improvements consistently across all treatment arms in both studies.

The incidence of ocular adverse events in the study eye was 49.7%, 49.2% and 45.4% and non-ocular adverse events was 73.0%, 74.2%, and 75.7% through Week 100, in the faricimab Q8W, faricimab up to Q16W, and aflibercept Q8W arms, respectively (see section 4.4 and 4.8).

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with faricimab in all subsets of the paediatric population in nAMD and DME (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Faricimab is administered intravitreally to exert local effects in the eye.

Absorption and distribution

Based on a population pharmacokinetic analysis (including nAMD and DME N = 2,246), maximum free (unbound to VEGF-*A* and *Ang-2*) faricimab plasma concentrations (C_{max}) are estimated to occur approximately 2 days post-dose. Mean (\pm SD [standard deviation]) plasma C_{max} are estimated 0.23 (0.07) μ g/mL and 0.22 (0.07) μ g/mL respectively in nAMD and in DME patients. After repeated administrations, mean plasma free faricimab trough concentrations are predicted to be 0.002-0.003 μ g/mL for Q8W dosing.

Faricimab exhibited dose-proportional pharmacokinetics (based on C_{max} and AUC) over the dose range 0.5 mg-6 mg. No accumulation of faricimab was apparent in the vitreous or in plasma following monthly dosing.

Maximum plasma free faricimab concentrations are predicted to be approximately 600 and 6000-fold lower than in aqueous and vitreous humour respectively. Therefore, systemic pharmacodynamic effects are unlikely, further supported by the absence of significant changes in free VEGF and Ang-2 concentration in plasma upon faricimab treatment in clinical studies.

Population pharmacokinetic analysis has shown an effect of age and body weight on ocular or systemic pharmacokinetics of faricimab respectively. Both effects were considered not clinically meaningful; no dose adjustment is needed.

Biotransformation and elimination

Faricimab is a protein-based therapeutic hence its metabolism and elimination have not been fully characterised. Faricimab is expected to be catabolised in lysosomes to small peptides and amino acids, which may be excreted renally, in a similar manner to the elimination of endogenous IgG.

The faricimab plasma concentration-time profile declined in parallel with the vitreous and aqueous concentration-time profiles. The estimated mean ocular half-life and apparent systemic half-life of faricimab is 7.5 days.

Special populations

Elderly

In the four Phase III clinical studies, approximately 60% (1,149/1,929) of patients randomised to treatment with faricimab were \geq 65 years of age. Population pharmacokinetic analysis has shown an effect of age on ocular pharmacokinetics of faricimab. The effect was considered not clinically meaningful. No dose adjustment is required in patients 65 years and above (see section 4.2).

Renal impairment

No specific studies in patients with renal impairment have been conducted with faricimab. Pharmacokinetic analysis of patients in the four Phase III clinical studies of which 64% had renal impairment (mild 38%, moderate 24%, and severe 2%), revealed no differences with respect to systemic pharmacokinetics of faricimab after intravitreal administration of faricimab. No dose adjustment is required in patients with renal impairment (see section 4.2).

Hepatic impairment

No specific studies in patients with hepatic impairment have been conducted with faricimab. However, no special considerations are needed in this population because metabolism occurs via proteolysis and does not depend on hepatic function. No dose adjustment is required in patients with hepatic impairment (see section 4.2).

Other special populations

The systemic pharmacokinetics of faricimab are not influenced by race. Gender was not shown to have a clinically relevant influence on systemic pharmacokinetics of faricimab. No dose adjustment is needed.

5.3 Preclinical safety data

No studies have been conducted on the carcinogenic or mutagenic potential of faricimab.

In pregnant cynomolgus monkeys, IV injections of faricimab resulting in serum exposure (C_{max}) more than 500-times the maximum human exposure did not elicit developmental toxicity or teratogenicity, and had no effect on weight or structure of the placenta, although, based on its pharmacological effect faricimab should be regarded as potentially teratogenic and embryo-/foetotoxic.

Systemic exposure after ocular administration of faricimab is very low.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

L-histidine
Acetic acid 30% (for pH adjustment)
L-methionine
Polysorbate 20
Sodium chloride
D-sucrose
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

30 months

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Prior to use, the unopened vial may be kept at room temperature, 20°C to 25°C, for up to 24 hours.

Ensure that the injection is given immediately after preparation of the dose.

6.5 Nature and contents of container

0.24 mL sterile, solution in a glass vial with a coated rubber stopper sealed with an aluminum cap with a yellow plastic flip-off disk.

Pack size of 1 vial and 1 blunt transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm, 5 µm).

6.6 Special precautions for disposal and other handling

Do not shake.

The vial contains more than the recommended dose of 6 mg. The fill volume of the vial (0.24 mL) is not to be used in total. The excess volume should be expelled prior to injection. Injecting the entire volume of the vial results in overdose. The injection dose must be set to the 0.05 mL dose mark, i.e. 6 mg faricimab.

Vabysmo should be inspected visually upon removal from the refrigerator and prior to administration. If particulates or cloudiness are visible, the vial must not be used.

The contents of the vial and the transfer filter needle are sterile and for single use only. Do not use if the packaging, vial and/or transfer filter needle are damaged or expired. Detailed instructions for use are provided in the package leaflet.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
Grenzach-Wyhlen
79639
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1683/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation:

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

ANNEX II

- A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) of the biological active substance(s)

Roche Diagnostics GmbH
Nonnenwald 2
Penzberg
82377
Germany

Name and address of the manufacturer(s) responsible for batch release

Roche Pharma AG
Emil-Barell-Str 1
Grenzach-Whylen
79639
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this medicinal product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

- **Additional risk minimisation measures**

Prior to the launch of Vabysmo in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The educational programme is aimed at adequately informing patients/carers on the risks of Vabysmo, the key signs and symptoms of those risks, and when to seek urgent attention from their physician with the objective to minimize the risks and any resultant complications by encouraging prompt intervention.

The MAH shall ensure that in each Member State where Vabysmo is marketed, all patients/carers who are expected to use Vabysmo have access to/are provided with the following educational package:

- Patient information pack

The patient information pack consists of the patient information leaflet and a patient/carer guide. The patient guide is provided in written and audio format, and will include the following key elements:

- A description of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
- A description of Vabysmo, how it works, and what to expect from Vabysmo treatment
- A description of the key signs and symptoms of the key risks associated with Vabysmo, i.e., infectious endophthalmitis and intraocular inflammation
- A description of when to seek urgent attention from the health care provider should signs and symptoms of these risks present themselves
- Recommendations for adequate care after the injection

- **Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

Description	Due date
A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with nAMD	Q1 2025
A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with DME	Q4 2024

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CARTON**

1. NAME OF THE MEDICINAL PRODUCT

Vabysmo 120 mg/mL solution for injection
faricimab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

One mL of solution contains 120 mg of faricimab.
Each vial contains 28.8 mg faricimab (120 mg/mL).

3. LIST OF EXCIPIENTS

Also contains: L-histidine, acetic acid, L-methionine, polysorbate 20, sodium chloride, sucrose, water
for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
1 x 0.24 mL vial
1 filter needle

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Single use only
Read the package leaflet before use
Intravitreal use
Single dose: 6 mg/0.05 mL
28.8 mg/0.24 mL

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator
Do not freeze
Keep the vial in the outer carton in order to protect from light

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1683/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
VIAL**

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Vabysmo 120 mg/mL solution for injection
faricimab
Intravitreal use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

28.8 mg/0.24 mL

6. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

Vabysmo 120 mg/mL solution for injection faricimab

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor.
- If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Vabysmo is and what it is used for
2. What you need to know before you receive Vabysmo
3. How to use Vabysmo
4. Possible side effects
5. How to store Vabysmo
6. Contents of the pack and other information

1. What Vabysmo is and what it is used for

What Vabysmo is and what it is used for

Vabysmo contains the active substance faricimab, which belongs to a group of medicines called antineovascularisation agents.

Vabysmo is injected into the eye by your doctor to treat eye disorders in adults called:

- neovascular (wet) age-related macular degeneration (nAMD),
- visual impairment due to diabetic macular oedema (DME).

These disorders affect the macula, the central part of the retina (the light-sensitive layer at the back of the eye) that is responsible for fine, central vision. nAMD is caused by the growth of abnormal blood vessels which leak blood and fluid into the macula, and DME is caused by leaky blood vessels that cause swelling of the macula.

How Vabysmo works

Vabysmo specifically recognises and blocks the activity of proteins known as angiopoietin-2 and vascular endothelial growth factor A. When these proteins are present at higher levels than normal, they can cause growth of abnormal blood vessels and/or damage to normal vessels, with leakage into the macula, causing swelling or damage that can negatively affect a person's vision. By attaching to these proteins, Vabysmo can block their actions and prevent abnormal vessel growth, leakage and swelling. Vabysmo may improve the disease and/or slow down worsening of the disease and thereby maintain, or even improve, your vision.

2. What you need to know before you receive Vabysmo

You should not receive Vabysmo:

- if you are allergic to faricimab or any of the other ingredients of this medicine (listed in section 6).
- if you have an active or suspected infection in or around the eye.
- if you have pain or redness in your eye (eye inflammation).

If any of these apply to you, tell your doctor. You should not be given Vabysmo.

Warnings and precautions

Talk to your doctor before receiving Vabysmo:

- if you have glaucoma (an eye condition usually caused by high pressure in the eye).
- if you have a history of seeing flashes of light or floaters (dark floating spots) and if you have a sudden increase in the size and number of floaters.
- if you have had eye surgery in the last four weeks or if eye surgery is planned in the next four weeks.
- if you have ever had any eye diseases or eye treatments.

Tell your doctor immediately if you:

- develop sudden vision loss.
- develop signs of a possible eye infection or inflammation, such as increased redness of the eye, eye pain, increased eye discomfort, blurred or decreased vision, an increased number of small particles in your vision, increased sensitivity to light.

Furthermore it is important for you to know that:

- the safety and efficacy of Vabysmo when administered to both eyes at the same time has not been studied and use in this way may lead to an increased risk of side effects.
- injections with Vabysmo may cause a temporary increase in eye pressure (intraocular pressure) in some patients within 60 minutes of the injection. Your doctor will monitor this after each injection.
- your doctor will check whether you have other risk factors that may increase the chance of a tear or detachment of one of the layers at the back of the eye (retinal detachment or tear, and retinal pigment epithelial detachment or tear), in which case Vabysmo must be given with caution.

When some medicines that work in a similar way to Vabysmo are given, there is known to be a risk of blood clots blocking blood vessels (arterial thromboembolic events), which may lead to heart attack or stroke. As small amounts of the medicine enter the blood, there is a theoretical risk of such events following injection of Vabysmo into the eye.

There is only limited experience in the treatment of:

- patients with active infections.
- patients with nAMD 85 years or older.
- patients with DME due to type I diabetes.
- diabetics with high average blood sugar values (Hb1c over 10%).
- diabetics with an eye disease caused by diabetes called proliferative diabetic retinopathy.
- diabetics with high blood pressure greater than 140/90 mmHg and disease of the blood vessels.
- patients with DME receiving injections less than every 8 weeks over a long period of time.

There is only limited experience in the treatment of patients receiving injections less than every 8 weeks over a long period of time, and these patients may be at greater risk of side effects.

There is no experience in the treatment of:

- diabetics with uncontrolled high blood pressure.

If any of the above applies to you, your doctor will consider this lack of information when treating you with Vabysmo.

Children and adolescents

The use of Vabysmo in children and adolescents has not been studied because nAMD and DME occur mainly in adults.

Other medicines and Vabysmo

Tell your doctor if you are using, have recently used or might use any other medicines.

Pregnancy and breast-feeding

Vabysmo has not been studied in pregnant women. Vabysmo should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the unborn child.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before this medicine is given to you.

Breast-feeding is not recommended during treatment with Vabysmo because it is not known whether Vabysmo passes into human milk.

Women who could become pregnant must use an effective method of birth control during treatment and for at least three months after stopping treatment with Vabysmo. If you become pregnant or think you are pregnant during treatment, tell your doctor right away.

Driving and using machines

After your injection with Vabysmo, you may have temporary vision problems (for example blurred vision). Do not drive or use machines as long as these last.

Vabysmo contains sodium

The medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free”.

3. How to use Vabysmo

How Vabysmo is given

The recommended dose is 6 mg of faricimab.

Neovascular (wet) age-related macular degeneration (nAMD)

- You will be treated with one injection every month for the first 4 months.
- After that, you may receive injections up to every 4 months. Your doctor will decide on the frequency of the injections based on the condition of your eye.

Visual impairment due to diabetic macular oedema (DME)

- You will be treated with one injection every month for the first 4 months.
- After that, you may receive injections up to every 4 months. Your doctor will decide on the frequency of the injections based on the condition of your eye.

Method of administration

Vabysmo is injected into your eye (intravitreal injection) by a doctor experienced in giving eye injections.

Before the injection your doctor will use a disinfectant eyewash to clean your eye carefully to prevent infection. Your doctor will give you an eye drop (local anaesthetic) to numb the eye to reduce or prevent pain from the injection.

How long does Vabysmo treatment last for

This is a long-term treatment, possibly continuing for months or years. Your doctor will regularly monitor your condition to check that the treatment is working. Depending on how you respond to the treatment with Vabysmo, your doctor may ask you to change to a more or less frequent dose.

If you miss a dose of Vabysmo

If you miss a dose, schedule a new appointment with your doctor as soon as possible.

If you stop using Vabysmo

Speak with your doctor before stopping treatment. Stopping treatment may increase your risk of vision loss and your vision may worsen.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The side effects with Vabysmo injection are either from the medicine itself or from the injection procedure and they mostly affect the eye.

Some side effects could be serious

Contact your doctor **immediately** if you have any of the following, which are signs of allergic reactions, inflammation or infections:

- eye pain, increased discomfort, increased eye redness, blurred or decreased vision, a higher number of small particles in your vision, or increased sensitivity to light – these are signs of a possible eye infection, inflammation, or allergic reaction.
- a sudden decrease or change in vision.

Other possible side effects

Other side effects which may occur after Vabysmo treatment include those listed below.

Most of the side effects are mild to moderate and will generally disappear within a week after each injection.

Contact your doctor if any of the following side effects become severe.

Very common (may affect more than 1 in 10 people):

- Cloudy lens in the eye (cataract)

Common (may affect up to 1 in 10 people):

- Tearing of the retina (the layer at the back of the eye that detects light) or one of its layers

- Increase in pressure inside the eye (increased intraocular pressure)
- Bleeding from small blood vessels in the outer layer of the eye (conjunctival haemorrhage)
- Moving spots or dark shapes in your vision (vitreous floaters)
- Eye pain
- Increased tear production (increased lacrimation)

Uncommon (may affect up to 1 in 100 people):

- Serious inflammation or infection inside the eye (endophthalmitis)
- Inflammation of the gel-like substance inside the eye/red eye (vitritis)
- Inflammation in the iris and its adjacent tissue in the eye (iritis, iridocyclitis, uveitis)
- Bleeding inside the eye (vitreous haemorrhage)
- Scratched cornea, damage to the clear layer of the eyeball that covers the iris (corneal abrasion)
- Eye irritation
- Eye discomfort
- Itching (eye pruritus)
- Red eye (ocular/conjunctival hyperaemia)
- A feeling of having something in the eye
- Blurred vision
- Decreased sharpness of vision (visual acuity reduced)

Rare (may affect up to 1 in 1,000 people):

- Detachment of the retina
- Temporary decreased sharpness of vision (visual acuity reduced transiently)

When some medicines that work in a similar way to Vabysmo are given, there is known to be a risk of blood clots blocking blood vessels (arterial thromboembolic events), which may lead to heart attack or stroke. As small amounts of the medicine enter the blood, there is a theoretical risk of such events following injection of Vabysmo into the eye.

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Vabysmo

Your doctor, pharmacist or nurse is responsible for storing this medicine and disposing of any unused product correctly. The following information is intended for healthcare professionals.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Prior to use, the unopened vial may be kept at room temperature, 20°C to 25°C, for up to 24 hours.

6. Contents of the pack and other information

What Vabysmo contains

- The active substance is faricimab. One mL solution for injection contains 120 mg faricimab. Each vial contains 28.8 mg faricimab in 0.24 mL solution. This provides a usable amount to deliver a single dose of 0.05 mL solution containing 6 mg of faricimab.
- The other ingredients are: L-histidine, acetic acid 30%, L-methionine, sodium chloride, sucrose, polysorbate 20, water for injections.

What Vabysmo looks like and contents of the pack

Vabysmo is a clear to opalescent, colourless to brownish-yellow solution.

Pack size of one glass vial and one sterile 5 µm blunt transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm) for single-use only.

Marketing Authorisation Holder

Roche Registration GmbH
Emil-Barell-Strasse 1
Grenzach-Wyhlen
79639
Germany

Manufacturer

Roche Pharma AG
Emil-Barell-Str 1
Grenzach-Whylen
79639
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

N.V. Roche S.A.
Tél/Tel: +32 (0) 2 525 82 11

България

Рош България ЕООД
Тел: +359 2 818 44 44

Česká republika

Roche s. r. o.
Tel: +420 - 2 20382111

Danmark

Roche a/s
Tlf: +45 - 36 39 99 99

Lietuva

UAB "Roche Lietuva"
Tel: +370 5 2546799

Luxembourg/Luxemburg

(Voir/siehe Belgique/Belgien)

Magyarország

Roche (Magyarország) Kft.
Tel: +36 - 1 279 4500

Malta

(See Ireland)

Deutschland

Roche Pharma AG
Tel: +49 (0) 7624 140

Eesti

Roche Eesti OÜ
Tel: + 372 - 6 177 380

Ελλάδα

Roche (Hellas) A.E.
Τηλ: +30 210 61 66 100

España

Roche Farma S.A.
Tel: +34 - 91 324 81 00

France

Roche
Tél: +33 (0)1 47 61 40 00

Hrvatska

Roche d.o.o.
Tel: + 385 1 47 22 333

Ireland

Roche Products (Ireland) Ltd.
Tel: +353 (0) 1 469 0700

Ísland

Roche a/s
c/o Icepharma hf
Sími: +354 540 8000

Italia

Roche S.p.A.
Tel: +39 - 039 2471

Κύπρος

Γ.Α.Σταμάτης & Σια Λτδ.
Τηλ: +357 - 22 76 62 76

Latvija

Roche Latvija SIA
Tel: +371 - 6 7039831

Nederland

Roche Nederland B.V.
Tel: +31 (0) 348 438050

Norge

Roche Norge AS
Tlf: +47 - 22 78 90 00

Österreich

Roche Austria GmbH
Tel: +43 (0) 1 27739

Polska

Roche Polska Sp.z o.o.
Tel: +48 - 22 345 18 88.

Portugal

Roche Farmacêutica Química, Lda
Tel: +351 - 21 425 70 00

România

Roche România S.R.L.
Tel: +40 21 206 47 01

Slovenija

Roche farmacevtska družba d.o.o.
Tel: +386 - 1 360 26 00

Slovenská republika

Roche Slovensko, s.r.o.
Tel: +421 - 2 52638201

Suomi/Finland

Roche Oy
Puh/Tel: +358 (0) 10 554 500

Sverige

Roche AB
Tel: +46 (0) 8 726 1200

United Kingdom (Northern Ireland)

Roche Products (Ireland) Ltd.
Tel: +44 (0) 1707 366000

This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site:
<https://www.ema.europa.eu>.

<----->

The following information is intended for healthcare professionals only:

Before you start:

- Read all the instructions carefully before using Vabysmo.
- The Vabysmo kit includes a glass vial and transfer filter needle. The glass vial is for a single dose only. The filter needle is for single use only.
- Vabysmo should be stored refrigerated at temperatures between 2°C to 8°C.

Do not freeze.

Do not shake.

- Allow Vabysmo to reach room temperature, 20°C to 25°C before proceeding with the administration. Keep the vial in the original carton to protect from light.
- The Vabysmo vial may be kept at room temperature for up to 24 hours.
- The Vabysmo vial should be inspected visually prior to administration. Vabysmo is a clear to opalescent and colorless to brownish-yellow liquid solution.

Do not use if particulates, cloudiness, or discoloration are visible.

Do not use if the packaging, vial and/or transfer filter needle are expired, damaged, or have been tampered with (see **Figure A**).

- Use aseptic technique to carry out the preparation of the intravitreal injection.




Figure A

Instructions for use of vial:


1. Gather the following supplies:

- One Vabysmo vial (included)
- One sterile 5-micron blunt transfer filter needle 18-gauge x 1½ inch, 1.2 mm x 40 mm (included)
- One sterile 1 mL Luer lock syringe with a 0.05 mL dose mark (**not included**)
- One sterile injection needle 30-gauge x ½ inch (**not included**)

Note that a 30-gauge injection needle is recommended to avoid increased injection forces that could be experienced with smaller diameter needles.

- Alcohol swab (**not included**).


2. To ensure all liquid settles at the bottom of the vial, place the vial upright on a flat surface (for about 1 minute) after removal from packaging (see **Figure B**). Gently tap the vial with your finger (see **Figure C**), as liquid may stick to the top of the vial.



3. Remove the flip-off cap from the vial (see **Figure D**) and wipe the vial septum with an alcohol swab (see **Figure E**).



4. Aseptically and firmly attach the included 18-gauge x 1½ inch transfer filter needle onto a 1 mL Luer lock syringe (see **Figure F**).



5. Using aseptic technique, push the transfer filter needle into the center of the vial septum (see **Figure G**), push it all the way in, then tilt the vial slightly so that the needle touches the bottom edge of the vial (see **Figure H**).



6. Hold the vial slightly inclined and **slowly** withdraw all the liquid from the vial (see **Figure I**). Keep the bevel of the transfer filter needle submerged in the liquid, to avoid introduction of air.




Figure I

7. Ensure that the plunger rod is drawn sufficiently back when emptying the vial, in order to completely empty the transfer filter needle (see **Figure I**).
8. Disconnect the transfer filter needle from the syringe and dispose of it in accordance with local regulations.

Do not use the transfer filter needle for the intravitreal injection.

9. Aseptically and firmly attach a 30-gauge x ½ inch injection needle onto the Luer lock syringe (see **Figure J**).




Figure J

10. Carefully remove the plastic needle shield from the needle by pulling it straight off.
11. To check for air bubbles, hold the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see **Figure K**).




Figure K

12. Carefully expel the air from the syringe and needle, and **slowly** depress the plunger to align the rubber stopper tip to the 0.05 mL dose mark. The syringe is ready for the injection (see **Figure L**). Ensure that the injection is given **immediately** after preparation of the dose.




Figure L

13. Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.05 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.

Excess volume should be expelled prior to injection. The injection dose must be set to the 0.05 ml dose mark to avoid overdose.

Any waste material or unused medicinal product should be disposed of in accordance with local regulations.